{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:45:14Z","timestamp":1775605514209,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejso.2026.111419","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:40:04Z","timestamp":1768840804000},"page":"111419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential prognostic impact of clinicopathologic factors for late recurrence in ER-positive breast cancer according to menopausal status"],"prefix":"10.1016","volume":"52","author":[{"given":"Eun-Shin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2998-6727","authenticated-orcid":false,"given":"Mary Rose","family":"Calindas-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Pil","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeong-Gon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonshik","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejso.2026.111419_bib1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes: dealing with the diversity of breast cancer. Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111419_bib2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9793","key":"10.1016\/j.ejso.2026.111419_bib3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejso.2026.111419_bib4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2026.111419_bib5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V","volume":"34","author":"Colleoni","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9869","key":"10.1016\/j.ejso.2026.111419_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"18 Suppl","key":"10.1016\/j.ejso.2026.111419_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111419_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111419_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"10.1016\/j.ejso.2026.111419_bib10","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast cancer index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant Tamoxifen-To offer more? (aTTom) trial","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111419_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111419_bib12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111419_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Soft and Text Investigators and the International Breast Cancer Study Group","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejso.2026.111419_bib14","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111419_bib15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/0013164418817803","article-title":"Evaluation of variance inflation factors in regression models using latent variable modeling methods","volume":"79","author":"Marcoulides","year":"2019","journal-title":"Educ Psychol Meas"},{"issue":"10","key":"10.1016\/j.ejso.2026.111419_bib16","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/jnci\/djae128","article-title":"Epidemiology of early versus late recurrence among women with early-stage estrogen receptor-positive breast cancer in the pathways study","volume":"116","author":"Chua","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ejso.2026.111419_bib17","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3390\/jcm11092332","article-title":"Comparison of clinical and pathological factors affecting early and late recurrences in patients with operable breast cancer","volume":"11","author":"Yeked\u00fcz","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejso.2026.111419_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103604","article-title":"Risk factors for late recurrence and postrelapse survival in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy","volume":"73","author":"Ito","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2026.111419_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12885-016-2423-x","article-title":"Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor-positive breast cancer","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.ejso.2026.111419_bib20","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2006.10.3754","article-title":"Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea\u2014A report from the Korean breast cancer society","volume":"25","author":"Ahn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2026.111419_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.42663","article-title":"Age and late recurrence in young patients with ER-positive, ERBB2-negative breast cancer","volume":"7","author":"Shin","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ejso.2026.111419_bib22","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1200\/JCO.2010.28.9199","article-title":"Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?","volume":"29","author":"Anders","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111419_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-016-0736-y","article-title":"Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the carolina breast cancer study: a case-control study","volume":"18","author":"Chollet-Hinton","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"20","key":"10.1016\/j.ejso.2026.111419_bib24","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejso.2026.111419_bib25","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR-positive, HER2-negative, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111419_bib26","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111419_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2026.111419_bib28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2026.111419_bib29","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/jamaoncol.2017.1261","article-title":"Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades","volume":"3","author":"Esserman","year":"2017","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2026.111419_bib30","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2015.62.6630","volume":"34","author":"Wolmark","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:49:55Z","timestamp":1775602195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0748798326000387"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111419","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential prognostic impact of clinicopathologic factors for late recurrence in ER-positive breast cancer according to menopausal status","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111419"}}